You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Nixoa reported third-quarter 2026 net revenue of 9.2 million euro, up 365% year over year, and updated full-year 2026 guidance to €33 million to €35 million. Cash, cash equivalents and financial assets totaled €77.1 million.
Nyxoah SA reported Q3 2026 global net revenue of €9.2 million and 29% sequential U.S. revenue growth. It submitted a Genio PMA supplement seeking expansion of the U.S. indication to Complete Concentric Collapse patients.
Nyxoah SA lowered 2026 global net revenue guidance to €33 million to €35 million from €36 million to €40 million. It submitted a PMA supplement seeking to expand Genio’s U.S. indication to Complete Concentric Collapse patients.
Nyxoah SA appointed Liam Kelly as Chief Executive Officer effective October 1, 2026, succeeding Olivier Taelman, as part of its transition toward a U.S.-focused commercial organization following FDA approval and the launch of Genio.
Nyxoah SA announced that John Landry will step down as Chief Financial Officer effective October 2, 2026; Loïc Moreau will serve as Interim Chief Financial Officer while the company searches for a permanent successor and reaffirms full year 2026 financial guidance.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NYXH
this stock
Nyxoah SA
|
$91.61M | -80.4% | — | — | 0.3% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Nyxoah SA reported Q3 2026 global net revenue of €9.2 million and 29% sequential U.S. revenue growth. It submitted a Genio PMA supplement seeking expansion of the U.S. indication to Complete Concentric Collapse patients.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NYXH | +6.4% | -19.0% | -66.7% | +3.2% | -80.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +3.8% | -17.8% | -67.2% | +3.4% | -91.1% |
